H HiPerformance CultureThe Evidence
Bio 5 min read
Trend Breakdown
The Evidence

Do performance peptides live up to the hype?

Performance peptides sit on real pharmacology: GH-axis compounds genuinely elevate IGF-1, and BPC-157 heals tissue in animal models. The problem is the gap between hormone levels and actual performance. Three systematic reviews and a clinical trial find no strength or aerobic gains, and a documented cancer risk signal deserves a plain hearing.

Updated Published 3 Jun 2026 · Last reviewed 3 Jun 2026 · 6 sources
Skip to the verdict ↓
Trend Science
Breakdown
Evidence-graded series
02What's being claimed

Performance peptides rebuild tissue faster than the body can alone, restore the youthful GH pulses that decline after 30, and offer a legal route to gains that once required anabolic drugs. Proponents point to proven pharmacology: GH and IGF-1 do rise in pharmacokinetic trials, and the endpoints (lean mass, recovery, hormonal optimisation) are genuinely relevant to performance.

Growth hormone declines measurably after 30, and GH secretagogues (compounds that stimulate the pituitary to release GH rather than injecting it directly) offered something the anabolic-steroid era never had: a pharmacologically legitimate mechanism that sat in a legal grey area. The early case rested on real laboratory endpoints: GH and IGF-1 rise reliably when these compounds are administered, as shown in controlled pharmacokinetic trials 12. Alongside the GH-axis compounds, BPC-157 and TB-500 accumulated a substantial preclinical record showing tissue healing acceleration across tendon, ligament, bone, and muscle 4.

The trend consolidated around high-credibility proponents: physicians and podcasters with large audiences began recommending GH secretagogues as injectable HGH alternatives from around 2020, citing peer-reviewed pharmacology rather than bodybuilder forums. That gave the trend a scientific legitimacy that most performance supplements never achieve, which is exactly what makes the gap between the hormone data and the performance data consequential.

Origin
Anti-ageing medicine
US anti-ageing clinics prescribed HGH off-label from the late 1990s to restore 'youthful physiology'.
→
Vector
Longevity podcasters
Prominent physicians and podcasters began recommending GH secretagogues as injectable HGH alternatives from 2020.
→
Spike
Bodybuilding TikTok
BPC-157 and peptide stacks spread as 'injury-healing' and 'muscle-building' protocols on social media from 2022.
"BPC-157 healed my torn shoulder in six weeks. CJC-1295 and ipamorelin stacked with a training protocol gave me the body composition I spent five years chasing. The research is solid; you just have to know where to look."
— Representative of claims circulating in fitness and longevity communities online
03The evidence verdict
H
HiPerformance Culture The Evidence · Trend Breakdown
Verdict

GH peptides shift body composition, not performance. BPC-157 has no human trial data. The cancer risk signal is real.

Hype Evidence
This trend lands here
Low Moderate High
Low confidence 6 sources cited · 3 systematic reviews/meta-analyses, 1 RCT, 1 prospective cohort, 1 individual-participant meta-analysis · 2008-2025
✓

What holds up

✓
GH-axis peptides reliably elevate endogenous GH and IGF-1 in controlled human trials. 1
Gold
✓
GH secretagogues produce modest lean-mass gains: a 2-year RCT found +1.1 kg fat-free mass in healthy older adults, with no improvement in strength. 3
Silver
✓
BPC-157 consistently accelerates musculoskeletal healing in animal models across tendon, muscle, ligament, and bone. 4
Bronze
✕

What doesn't

✕
No improvement in muscle strength, power, or aerobic capacity from GH/IGF-1 elevation in healthy adults, across three systematic reviews and a 2-year RCT. 1
Gold
✕
No completed human RCT exists for BPC-157 or injectable TB-500 for musculoskeletal performance or recovery. The FDA prohibited BPC-157 compounding in the United States in 2023. 4
Gold
✕
Sustained IGF-1 elevation is associated with significantly increased breast cancer (HR 1.25) and prostate cancer (HR 1.31) risk in large prospective datasets. 5
Safety-critical Gold
✕
MK-677 (2-year RCT) produced increased appetite in 67% of participants, oedema in 44%, and raised fasting glucose indicating insulin resistance. 3
Safety-critical Silver
04The studies
Scored on Design quality Measurement precision Causal clarity Replication value
Gold
0/44 studies showing improved athletic performance from GH
Systematic review · n=303
Liu et al. Annals of Internal Medicine · 2008
Across 44 studies and 303 participants receiving GH, lean body mass increased but strength did not improve. GH may worsen exercise capacity and significantly increased adverse events. Liu et al. conclude there is no evidence that GH enhances athletic performance {{cite:10.7326/0003-4819-148-10-200805200-00215}}.
doi:10.7326/0003-4819-148-10-200805200-00215 Verify ↗
Gold
p=0.36 muscle strength p-value, no significant effect from GH
Systematic review and meta-analysis · n=254
Hermansen et al. Growth Hormone & IGF Research · 2017
GH administration significantly increased lean body mass and decreased fat mass in healthy young adults, but did not improve muscle strength (p=0.36) or maximal oxygen uptake (p=0.89) {{cite:10.1016/j.ghir.2017.05.005}}. Only one of eleven trials showed any anaerobic performance benefit.
doi:10.1016/j.ghir.2017.05.005 Verify ↗
Gold
+1.1 kg fat-free mass gained over 2 years, no improvement in strength
2-year RCT · n=65
Nass et al. Annals of Internal Medicine · 2008
MK-677 at 25 mg/day raised GH 1.8-fold and IGF-1 1.5-fold, increasing fat-free mass by 1.1 kg over 24 months. Muscle strength and physical function showed no improvement. Adverse effects included increased appetite (67% of participants), oedema (44%), and raised fasting glucose, indicating insulin resistance {{cite:10.7326/0003-4819-149-9-200811040-00003}}.
doi:10.7326/0003-4819-149-9-200811040-00003 Verify ↗
Gold
0 completed human RCTs for BPC-157 in musculoskeletal use
Systematic review · 36 studies
Vasireddi et al. HSS Journal · 2025
Of 544 abstracts screened, 35 included studies were all preclinical animal models; only one was a small retrospective human study (n=12-16) for BPC-157. No completed human RCTs exist. The FDA designated BPC-157 a Category 2 bulk drug substance in 2023, prohibiting its compounding in the United States {{cite:10.1177/15563316251355551}}.
doi:10.1177/15563316251355551 Verify ↗
Gold
HR 1.31 elevated prostate cancer risk at highest IGF-1 quintile
Case-cohort prospective · n=7,461
Mukama et al. Journal of Clinical Endocrinology & Metabolism · 2023
Mukama et al. found that a higher IGF-1 quintile is associated with significantly increased breast cancer risk (HR=1.25) and prostate cancer risk (HR=1.31) in the EPIC-Heidelberg cohort. Both very low and very high IGF-1 quintiles carry elevated all-cause and cancer mortality, consistent with a U-shaped risk curve {{cite:10.1210/clinem/dgad212}}.
doi:10.1210/clinem/dgad212 Verify ↗
Gold
OR 1.29 prostate cancer risk increase, highest vs lowest IGF-1 fifth
Individual-participant data meta-analysis · n=24,172
Travis et al. Cancer Research · 2016
Travis et al. assembled the largest dataset on IGF-I and prostate cancer, comprising 17 prospective and 2 cross-sectional studies. IGF-I was independently and positively associated with prostate cancer risk (OR approximately 1.29, highest vs lowest fifth), and remained the sole significant analyte after mutual adjustment for related biomarkers {{cite:10.1158/0008-5472.can-15-1551}}.
doi:10.1158/0008-5472.can-15-1551 Verify ↗
05So what do you actually do

If you want to pursue peptide therapy, the evidence supports one narrow, supervised use case.

For healthy adults chasing performance gains, the risk-benefit ratio does not support unsupervised use.

01If you have documented GH deficiency, seek an endocrinologist assessment before any secretagogue protocol.
02Do not use BPC-157 or TB-500 for injury recovery: the human RCT evidence does not yet exist to support it.
03Prioritise the training stimulus that naturally drives IGF-1: progressive overload and adequate dietary protein.
04If you pursue any GH-axis compound, monitor IGF-1 levels and treat sustained elevation as a risk signal, not a target.
05Avoid self-administering peptide stacks based on social media protocols; the adverse effect profile is real and poorly characterised.
06The verdict triad
Claim

Peptides Restore Youth, Rebuild Tissue

Proponents argue that GH-axis peptides restore the hormonal environment of early adulthood, and that compounds like BPC-157 accelerate tissue repair beyond what the body can do unaided. The pharmacology is real: GH and IGF-1 do rise, and animal healing data is consistent and replicated.

Consequence

IGF-1 Elevation Carries Cancer Risk

Raising IGF-1 via GH-axis peptides is not a neutral act. Large prospective datasets (EPIC-Heidelberg, n=7,461; prostate meta-analysis, n=24,172) find that the highest IGF-1 quintile carries meaningfully elevated breast and prostate cancer risk. In healthy adults, GH or IGF-1 elevation produces no performance benefit to offset that signal.

Lever

Train First, Treat the Deficit

Progressive resistance training is the documented driver of IGF-1 signalling in healthy muscle. For performance goals, the evidence points to training load and dietary protein, not hormonal shortcuts. For genuine GH deficiency, consult an endocrinologist: the condition is diagnosable and the treatment pathway is established.

08What to do next
What to do next

Could your hormonal profile be holding back your performance?

Our Performance Biology Assessment evaluates your GH-axis markers, recovery capacity, and body composition trajectory against peer-reviewed reference ranges. Peptide therapy may be relevant for a documented deficiency; for most, the protocol will point elsewhere.

Take the assessment
09Share & references
Update log
3 Jun 2026Article published. 6 sources reviewed; meter set to Low (22/100) based on consistent null performance findings across three systematic reviews and a 2-year RCT, with safety-critical cancer risk signal from two large prospective datasets.
Related
Owning guide
The HPC Performance Biology Guide
Evidence-based frameworks for optimising your hormonal environment through training, nutrition, and sleep.
Read the guide →
Assessment
Performance Biology Assessment
Map your GH-axis and recovery markers against clinical benchmarks.
Start assessment →
Trend Breakdown
Zone 2 Cardio: Real Endurance Adaptation or Trend?
How the evidence for low-intensity training stacks up against its viral claims.
Read the breakdown →
Bibliography · every source, resolvable
01Liu, H., Bravata, D.M., Olkin, I., Friedlander, A., Liu, V., Roberts, B., Bendavid, E., Saynina, O., Salpeter, S.R., Garber, A.M. & Hoffman, A.R. (2008). Systematic Review: The Effects of Growth Hormone on Athletic Performance. Annals of Internal Medicine, 148(10), 747-758. doi:10.7326/0003-4819-148-10-200805200-00215 Verify ↗Gold
02Hermansen, K., Bengtsen, M., Kjær, M., Vestergaard, P. & Jørgensen, J.O.L. (2017). Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials. Growth Hormone & IGF Research, 34, 38-44. doi:10.1016/j.ghir.2017.05.005 Verify ↗Gold
03Nass, R., Pezzoli, S.S., Oliveri, M.C., Patrie, J.T., Harrell, F.E., Clasey, J.L., Heymsfield, S.B., Bach, M.A., Vance, M.L. & Thorner, M.O. (2008). Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults. Annals of Internal Medicine, 149(9), 601-611. doi:10.7326/0003-4819-149-9-200811040-00003 Verify ↗Gold
04Vasireddi, N., Hahamyan, H., Salata, M.J., Karns, M., Calcei, J.G., Voos, J.E. & Apostolakos, J.M. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 21(4), 485-495. doi:10.1177/15563316251355551 Verify ↗Gold
05Mukama, T., Srour, B., Johnson, T., Katzke, V. & Kaaks, R. (2023). IGF-1 and Risk of Morbidity and Mortality From Cancer, Cardiovascular Diseases, and All Causes in EPIC-Heidelberg. The Journal of Clinical Endocrinology & Metabolism, 108(10), e1092-e1105. doi:10.1210/clinem/dgad212 Verify ↗Gold
06Travis, R.C., Appleby, P.N., Martin, R.M., Holly, J.M., Albanes, D., Black, A., Bueno-de-Mesquita, H.B., Chan, J.M., Chen, C., Chirlaque, M., Cook, M.B., Deschasaux, M., Donovan, J.L., Ferrucci, L., Galan, P., Giles, G.G., Giovannucci, E.L., Gunter, M.J., Habel, L.A., Hamdy, F.C., Helzlsouer, K.J., Hercberg, S., Hoover, R.N., Janssen, J.A., Kaaks, R., Kubo, T., Le Marchand, L., Metter, E.J., Mikami, K., Morris, J.K., Neal, D.E., Neuhouser, M.L., Ozasa, K., Palli, D., Platz, E.A., Pollak, M.N., Price, A.J., Roobol, M.J., Schaefer, C., Schenk, J.M., Severi, G., Stampfer, M.J., Stattin, P., Tamakoshi, A., Tangen, C.M., Touvier, M., Wald, N.J., Weiss, N.S., Ziegler, R.G., Key, T.J. & Allen, N.E. (2016). A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research, 76(8), 2288-2300. doi:10.1158/0008-5472.can-15-1551 Verify ↗Gold
Build better performance.
Get the 90-day protocol.